Consumer Staples

cbdMD Supports Proposed Hemp Guardrails Act Ahead of December 11 Regulatory Change

cbdMD says the proposed Hemp Guardrails Act could establish federal requirements for hemp-derived products and prevent a December 11, 2026 redefinition from removing a broad range of lawful products from the market.

Published:
Reading Time
3 min

cbdMD, Inc. (NYSE American:YCBD) has announced its support for the proposed Hemp Guardrails Act, bipartisan legislation introduced by Senators Tim Sheehy (R-MT) and Amy Klobuchar (D-MN) on November 17. The company says the bill would create federal standards for hemp-derived products before a redefinition scheduled to take effect on December 11, 2026.

#Proposed federal standards for hemp products

The legislation would set requirements for the sale and manufacture of hemp-derived cannabinoid products. Sales would be limited to adults 21 and older, while packaging would need to be child-resistant and include QR codes connecting consumers with third-party certificates of analysis.

The proposal would also direct the FDA to establish rules covering manufacturing, product testing, facility registration and recalls. Hemp would be required to be grown, processed and packaged in the United States.

Under the proposed framework, hemp products could not contain more than trace amounts of intoxicating cannabinoids other than delta-9 THC and a few other compounds. The bill would also retain the restriction on synthetic cannabinoids that do not occur naturally in the hemp plant.

#Company response to the December 11 deadline

cbdMD Chief Executive Officer Ronan Kennedy said the company supports regulation focused on consumer protections while retaining lawful agricultural, manufacturing and retail activity. The company said the hemp sector supports an estimated 350,000 American jobs across farmers, manufacturers, distributors and retailers, and contributes tax revenue to states and local communities.

cbdMD says the redefinition due to take effect on December 11 would remove a broad range of lawful hemp-derived products from the market if Congress does not act. Kennedy has urged Congress to include the proposed legislation in the year-end funding package before that date.

The Hemp Guardrails Act remains proposed legislation. The source material identifies the bill's passage in its current form as a risk affecting the company's forward-looking statements.

#cbdMD's broader wellness portfolio

cbdMD said its acquisition of the Twinlab, Metabolife and Reserveage brands expanded its nutritional supplement business beyond products dependent on hemp-derived cannabinoids. The company's stated brand portfolio also includes ResVitale, cbdMD, Paw CBD, Oasis and Bluebird Botanicals.

The company describes its products as being sold through retail, wholesale and direct-to-consumer channels. It is headquartered in Charlotte, North Carolina, and said it has invested in product safety through third-party testing and published research on its ingredients.

cbdMD said it is prepared to work with lawmakers and the FDA on implementation of the proposed framework. The company also said the broader supplement portfolio would provide a federal pathway for hemp-derived dietary supplements if the legislation passes, although the bill's outcome and final form remain unsettled.

#Key Takeaways

  • cbdMD supports the proposed Hemp Guardrails Act introduced by Senators Tim Sheehy and Amy Klobuchar on November 17.
  • The bill would set age-21 sales rules, packaging and testing requirements, FDA standards and cannabinoid restrictions.
  • Hemp would have to be grown, processed and packaged in the United States under the proposal.
  • cbdMD says a December 11, 2026 redefinition could remove a broad range of lawful hemp-derived products from the market.
  • The company has expanded its supplement portfolio through the Twinlab, Metabolife and Reserveage brands.

Original source: Read original article

Frequently Asked Questions